Cumulative live birth rates in cohorts of patients treated with in vitro fertilization or intracytoplasmic sperm injection
|
|
- Juliet Griffith
- 5 years ago
- Views:
Transcription
1 Cumulative live birth rates in cohorts of patients treated with in vitro fertilization or intracytoplasmic sperm injection Cynthia Witsenburg, M.D., Sandra Dieben, M.D., Lucette Van der Westerlaken, M.Sc., Harjo Verburg, M.D., and Nico Naaktgeboren, Ph.D. IVF Center, Leiden University Medical Center, Leiden, The Netherlands Objective: Follow-up of IVF/intracytoplasmic sperm injection (ICSI) patients to obtain accurate information concerning chances of live birth as well as early treatment dropout. Comparison of the cumulative pregnancy rates, established in cohorts, with those estimated with life table analysis to determine which method provides the most accurate data without overestimation. Design: Retrospective longitudinal cohort study. Setting: Academic medical IVF center. Patient(s): All 750 patients from the Leiden IVF center and another 706 patients from cooperating clinics starting IVF/ICSI treatment in the period Intervention(s): All observations were part of standard IVF/ICSI and cryopreservation protocols. Main Outcome Measure(s): Endpoints of this study were a first live birth or termination of treatment. Treatment cycles were followed until the end of 2002, pregnancy follow-up through September Result(s): The cumulative live birth rate for the Leiden cohort was 59.1%. In yearly cohorts this varied from 54.8% to 67.1%. Cumulative live birth rates were 61.8% 63.2% for unexplained infertility (n 229), endometriosis (n 19), and andrologic indication (n 223). For tubal (n 129) and hormonal (n 46) indications the rates were 55.8% and 45.7%, respectively. The group of egg donation or surrogacy (n 10) reached 40.0%, and patients with two or more indications (n 84) 56.0%. For women 35 years of age the cumulative live birth rate was 64.6%, for women years of age it was 48.7%, and for women years of age 31.0%. Conclusion(s): In contrast to estimation of expected cumulative pregnancy rates the cohort measurement does not overestimate success rates. It accurately reflects chances of both live birth as well as early treatment dropout. The cumulative live birth rate was 59.1%. Over time results improved and the contribution of cryopreservation increased. (Fertil Steril 2005;84: by American Society for Reproductive Medicine.) Key Words: Cumulative live birth rate, IVF/ICSI cohorts, cryopreservation, BESST Couples at the onset of IVF/intracytoplasmic sperm injection (ICSI) treatment are facing a pathway that is intense, uncertain, and not without risks. To avoid needless treatment with unnecessary disappointment and costs it is important to make accurate estimates of the chance of achieving a live birth as well as the chance of dropping out of the treatment program before that time. Knowledge about the multiple birth rate is also important. Since the introduction of IVF in 1978 (1) approximately 1,000,000 children have been born by means of IVF and ICSI treatments. Over the years results have become better, although the numbers of multiples remained too high. Most reports and registries consider pregnancy or birth rates per treatment cycle or embryo transfer (ET) (2 5). It is therefore not possible to determine whether the birth rate per patient increased to the same extent. For couples about to Received June 22, 2004; revised and accepted February 22, Reprint requests: Nico Naaktgeboren, Ph.D., IVF Center, Leiden University Medical Center H3-P-26, P.O. Box 9600, 2300 RC Leiden, The Netherlands (FAX: ; n.naaktgeboren@lumc.nl). start an IVF/ICSI treatment it is more important to know the ultimate chance of having a baby rather than the success rate per cycle. In this respect it is also important for the couples concerned to be correctly informed about the chance of achieving a single or multiple pregnancy and birth. A major challenge for the centers is to obtain the highest possible birth rate while reducing multiple births to a minimum. Some studies report success as cumulative (live) birth or pregnancy rates after multiple IVF/ICSI treatments (6 9). A popular tool for estimating the cumulative success rates is the life table analysis (10). However, using this type of analysis to report the outcome of fertility treatments is highly questionable because it tends to overestimate success rates. Some other investigators show both the observed and the expected values, but prefer to report the estimated outcome (11 13). Overestimation of results is also present in studies that use modified models that estimate the so called pessimistic, realistic, and optimistic or crude and expected cumulative live birth rates (CLBR) (14, 15). The fact that some patients drop out also influences the final cumulative success rate (16). Another way of presenting fertility /05/$30.00 Fertility and Sterility Vol. 84, No. 1, July 2005 doi: /j.fertnstert Copyright 2005 American Society for Reproductive Medicine, Published by Elsevier Inc. 99
2 treatment outcome was published in a recent debate: BESST (birth emphasizing a successful singleton at term) was proposed as the most relevant standard of success (17). It is our belief that the cohort study design in which couples are followed over a longer period of time will provide realistic information. It accurately reflects the chance of a live birth after IVF/ICSI treatment without overestimating success rates. It can also provide accurate data about both the singleton and multiple birth rates and information about the chance of early dropout of the treatment program. In this study we followed two cohorts of patients. One cohort consisted of 750 couples that started their first IVF/ ICSI treatment between 1996 and 2000 at the Leiden University Medical Center. The second cohort was formed by 706 patients from transport IVF clinics, cooperating with our laboratory. Endpoints of the follow-up were a first live birth or discontinuation of treatment. Treatment results and pregnancies were recorded through December The live birth rates are updated to the end of September Cohorts were arranged by year of treatment onset, indication for treatment, and woman s age at the start of the treatment. MATERIALS AND METHODS Patients Between January 1996 and December 2000, 750 couples started their first IVF/ICSI treatment at the Leiden University Medical Center (LUMC) in the Netherlands. This cohort of patients was followed until the end of During the same period of time another cohort of 706 patients, treated in cooperation with three so-called transport clinics was studied. For the latter patient group, counseling, stimulation, monitoring, and oocyte pickups are provided by the transport clinics themselves. The actual laboratory procedures, ET, and cryopreservation are taken care of by our center. The 750 LUMC patients were studied in yearly cohorts. Cohorts per indication and women s age at the start of treatment were defined as well. The number of patients starting treatment each year varied from 128 to 164. The average women s age at treatment onset was 33.0 ( 4.0) years. As divided by age, 523 (69.7%) women were 36, 195 (26.0%) 36 39, and 32 (4.3%) 39 years at the start of the treatment. Indications for IVF/ICSI treatment were andrologic (n 233, 31.1%), tubal (n 129, 17.2%), hormonal (n 46, 6.1%), endometriosis (n 19, 2.5%), unexplained (n 229, 30.5%), egg donation or surrogacy (n 10, 1.3%), and multiple indications (n 84, 11.2%). The 706 patients of the transport clinics were studied as one cohort. The average age at treatment onset in this cohort was 33.2 ( 5.2) years. Because IVF, ICSI, and embryo cryopreservation are proven methods for the treatment of infertility there was no need for institutional review board approval. An informed consent is not necessary for a standard IVF procedure; however, written informed consent to perform ICSI and/or cryopreservation was obtained. IVF/ICSI Treatment The LUMC patients were stimulated according to a standard short stimulation protocol, starting by downregulation with an GnRH agonist on the first day of the menstruation as a nasal spray (Synarel, 1.2 mg daily; Pharmacia BV, Woerden, The Netherlands) or SC (Decapeptyl, 1.0 mg daily; Ferring, Hoofddorp, The Netherlands). This was followed by ovarian stimulation with purified urinary FSH (Metrodin; Serono, Geneva, Switzerland) or recombinant FSH (Gonal F; Serono) starting either on day 4 with 150 IU when the women were 37 years of age or younger, or on day 2 with 225 or 300 IU if the women were or years of age, respectively. The patients were monitored by vaginal ultrasound scans and serum E 2 measurement. If necessary the dose was adjusted during stimulation or in the following treatment cycle. When desired follicle growth was achieved, hcg (Profasi, 10,000 IU; Serono) was given SC, followed by oocyte pickup 36 hours later. After 1,598 oocyte retrievals, fertilization was performed by conventional IVF (n 1,125; 70.4%) or ICSI (n 473; 29.6%) following standard techniques. In general, the ET took place 3 days after the oocyte pickup, the maximum number of embryos per transfer being 2 for women younger than 38 years and 3 for women 38 years of age and above (average 2.00 embryos per transfer). As luteal support, progesterone (Progestan, 600 mg daily; Organon Oss, The Netherlands) was given vaginally starting the day after the pickup, and additional hcg (Pregnyl, 1,500 IU; Organon) was given SC 3 days after the transfer. The ovarian stimulation protocols in the transport clinics were similar; the percentage of cycles with ICSI was also similar to those in the LUMC cohort (32%). Embryo Cryopreservation The surplus of good quality embryos were cryopreserved on day 3 or 4 after oocyte pickup, using dimethyl sulfoxide (DMSO) as cryoprotectant. Transfers of cryopreserved embryos were performed preferably in spontaneous cycles. Pregnancy Definition A live birth is used as the main outcome in this study. A pregnancy was defined as an increasing -hcg 50 IU/L at 15 days and more after oocyte retrieval. Ongoing pregnancy was defined by the presence of a gestational sac with fetal heart activity after at least 12 weeks of gestation. Cohort Analysis All initiated treatment cycles were included in the cohort analysis. A treatment cycle was defined as the start of hormonal stimulation of the ovary, whether or not this would 100 Witsenburg et al. Cohort follow-up of IVF/ICSI patients Vol. 84, No. 1, July 2005
3 lead to ET. Patients remained in the cohort until the first live birth occurred. Continuation of treatment after a nonviable pregnancy, or a longer interval without treatment, was considered as part of the original cohort. Patients that did not resume treatment before the end of this study in December 2002 were considered as treatment dropouts. Success rates refer to the number of patients that started their first cycle within a specific cohort. Frozen ET cycles were not counted as separate treatment cycles. Pregnancies and live births that resulted from frozen embryos were referred to the cycle from which the embryos initially originated. Such a referral system becomes especially meaningful when determining the cumulative treatment effect per patient (18, 19). Statistical Analysis Differences in observed success rates between groups were analyzed by means of nonparametric statistics ( 2 ). P.05 was considered to be significant. All tests were performed using SPSS software (SPSS, Chicago, IL). RESULTS All the initiated cycles of the 750 patients of the LUMC cohort were included in this cohort study. The patients were followed until they had a first live birth after IVF/ICSI treatment in a freshly stimulated cycle or after cryopreservation, or until they stopped treatment unsuccessfully. In Table 1 the treatment results and the cumulative results are summarized. The average number of treatment cycles per patient was 2.4. For these patients a total of 1,826 cycles was started in the period of January 1996 to December This resulted in 1,598 oocyte pickups (92.8%) and 1,483 ETs (81.2% per started cycle). The average number of retrieved oocytes per pickup was 8.60, with a mean of 2.02 embryos per transfer. The pregnancy rate was 30.3% per freshly stimulated cycle and 32.0% with the results of cryopreservation included. For 139 patients 204 transfers of frozen/thawed embryos took place after the fresh cycle did not result in a pregnancy followed by a live birth. This procedure resulted in 32 pregnancies followed by the live birth of 16 singletons and 4 sets of twins. The live birth rate per patient was 14.4%. Transfers of cryopreserved embryos accounted for 5.5% of all achieved pregnancies and for 4.5% of all achieved live births. Over time the contribution of cryopreservation increased and the multiple pregnancy rate decreased (Table 1). Ultimately, 75.6% of the pregnancies resulted in a live birth, 74.3% of them singletons, 24.8% twins, and 0.9% (n 4) triplets. Two of the 4 triplet births originated from double ET. The multiple birth rate in the 1999 and 2000 cohorts (average 20%) was significantly ( 2 df 1; P.02) lower than in the cohorts started between 1996 and 1998 (average 30%). The live birth rate was 24.3% per started treatment cycle, including the births originating from cryopreservation. The pregnancy rate per ET was 37.3%, and the live birth rate was 29.9%. After oocyte retrieval, IVF was performed in 1,125 cases (70.4%) and ICSI in 473 (29.6%). Exactly the same percentages were found for the number of live births resulting from IVF (n 312) and ICSI (n 131). Because it TABLE 1 Summary of treatment results and cumulative live birth rates Total No. of patients No. of cycles ,826 No. of cycles per patient No. of pregnancies No. of pregnancies after cryo a No. of pregnancies, cryo a included No. of abortion/eug No. of live births, excluding cryo a No. of live births after cryo a Total no. of live births, cryo a included Contribution of cryo a to total births (%) Live birth rate per cycle (%) Multiple birth rate b Cumulative live birth rate per patient (%) a cryo cryopreservation and transfers after thawing. b Results of were significantly higher than in 1999 and 2000 (P.017). Fertility and Sterility 101
4 TABLE 2 Live birth per cycle and cumulative live birth rate per patient. Cycle number No. of patients started No. of patients stopped No. of patients with a live birth (after cryo) 199 (11) 136 (4) 64 (4) 23 (0) 11 (1) 7 (0) 3 (0) Live birth rate per patient started in cycle X (%) Live birth rate per patient started in cohort (%) Cumulative live birth rate per patient (%) Cumulative singleton birth rate per patient (%) Note: Five patients continued after the 7th cycle; no pregnancies were established in the following treatment cycles. appeared that the effectiveness of IVF and ICSI is equal, the cohorts were not separated for type of treatment. A first IVF/ICSI treatment cycle resulted in a live birth for 26.5% of the patients. For a second, third, and fourth cycle this value was 27.7%, 21.4%, and 15.2%, respectively. Ultimately, the CLBR was 59.1%, with a mean treatment period of 11 months and an average of 2.4 cycles per patient (Table 2, Fig. 1). Over time the results improved. The CLBR in the different yearly cohorts varied from 54.8% in 1996 to 67.1% in The CLBR was 43.9% for singletons, 14.7% for twins, and 0.5% for triplets. No selective fetal reduction was performed. More than 95% of these pregnancies and live births were achieved within 3 years after treatment onset. When the patients indication for IVF/ICSI treatment was taken into account, the CLBRs were as follows: endometriosis (n 19, CLBR 63.2%), unexplained infertility (n 229, CLBR 62.4%), andrologic indication (n 233, CLBR 61.8%), tubal infertility (n 129, CLBR 55.8%), and hormonal dysfunction (n 46, CLBR 45.7%). For the subgroup with unexplained infertility using donor semen (n 62) the CLBR reached 74.2%. In the cohort of patients with 2 or more different indications (n 84) a CLBR of 56.0% was found (Table 3). Only patients with infertility due to hormonal dysfunction had a significantly lower CLBR than the group with unexplained infertility (P.034). There was no significant difference in the average number of treatment cycles per patient between any of the mentioned indications. The CLBR for the different age groups decreases significantly with age: 64.6% for women younger than 36 years of age (n 523), 48.7% for women aged years (n 195), and 31.3% for women aged years (n 32) at the start of treatment ( 2 df 2; P.005) (Table 4). Only 39 of the 750 patients (5.2%) continued treatment up to a sixth cycle. In total, after 6 treatment cycles 440 patients (58.7%) achieved a live birth, 296 patients (39.5%) concluded treatment without achieving a live birth, and 14 patients (1.9%) continued treatment. Three of them became pregnant (Fig. 1). The cumulative success rates are influenced by the dropout rate during an IVF treatment (16). Figure 2 shows the association between the cumulative dropout rate after 2 cycles and the observed success rate determined in our cohort of patients and from published data (9, 11, 13 16, 20, 21). The higher the success, the lower the dropout rate. Figure 3 compares the cohort of our 750 LUMC patients with the cohort of the 706 patients from the transport IVF FIGURE 1 Cumulative live birth and dropout rate after IVF/ ICSI as function of treatment cycle number. The live births are subdivided into singletons in the black bands, twin births in blue bands, and triplet births in yellow bands. Patients continuing treatment are in gray bands and patients that stopped further treatment are in red bands. 102 Witsenburg et al. Cohort follow-up of IVF/ICSI patients Vol. 84, No. 1, July 2005
5 TABLE 3 Cumulative live birth rates per indication. Patients Treatment cycles Live births One single indication Tubal (55.8%) Andrological (61.8%) Unexplained (all) a (62.4%) Unexplained with donor semen (74.2%) Unexplained with own semen (58.1%) Hormonal a (45.7%) Endometriosis (63.2%) Egg donation or surrogacy (40.0%) Subtotal with single indication 666 1, (59.5%) Multifactorial indication (56.0%) Total 750 1, (59.1%) Note: Data are presented as number (percent of started patients). a P.05 for patients with hormonal subfertility compared with patients with unexplained infertility. clinics. Almost identical live birth rates per treatment cycle were found for the transport cohort as for our own cohort (24.4% vs. 24.3%). The CLBR per patient however was significantly (P.001) lower for the cohort of the transport IVF clinics: 49.4% vs. 59.1% (Fig. 3). Table 5 compares the actual observed success rates in cohorts with the calculated expected success rates after 3 and 5 or more treatment cycles, as reported in several recent studies (6 9, 11 16, 20, 21). To objectively interpret these data we used the ratio expected/observed success rates to express the extent of overrating. This ratio tended to get higher as the actual observed cumulative birth rates decreased. In addition, we observed that the ratio increased with longer follow-up periods (Fig. 4). DISCUSSION In this cohort study, the mean CLBR for couples starting their first IVF/ICSI treatment cycle between January 1996 and December 2000 (n 750) at the Leiden University Medical Center was 59.1%. Most of these pregnancies (399 90%) were achieved within the first 3 treatment cycles. Only 39 patients (5.2%) continued treatment up to a sixth cycle. More than 95% of all treatments took place within the first 3 years from treatment onset; therefore, a follow-up period with a minimum of 3 years is necessary to obtain reliable data about the final pregnancy and live birth chances. This study showed that by means of the follow-up of patient cohorts reliable information can be gathered on the cumulative outcome in IVF/ICSI programs. Such information is useful for the patient and also can be applied to compare results between centers or countries. The ultimate take-home baby rate depends on both the live birth rate per treatment cycle as well as the number of treatments per patient. The comparison between the cohort of patients starting in our clinic and the transport clinic cohort illustrates that with an almost equal live birth rate per treatment cycle of 24% the CLBR per patient can be significantly (P.001) different (59.1% and 49.4%, respectively). This discrepancy can be explained by the lower number of TABLE 4 Cumulative live birth rate per age group. 35 y y 40 y Total No. of patients No. of live births Cumulative live birth rate per patient (%) 64.6 a 48.7 a 31.3 a 59.1 a Results are significantly different (P.005). Fertility and Sterility 103
6 FIGURE 2 Relation of cumulative dropout rate after 2 treatment cycles and observed cumulative success rate. The letters B I correspond to the references as indicated in Table 5; A the data from this study. treatment cycles per patient in the transport clinic group (1.98 vs. 2.43). The lower number of cycles per patient in the transport clinic cohort is associated with a higher dropout rate, which causes a lower CLBR. This illustrates that the observed CLBR per patient after follow-up of cohorts contained more realistic information for the patient than the live birth rate per cycle. The question arises how long one should continue IVF/ ICSI treatment if pregnancy is not achieved. The cumulative dropout rate after the first 2 cycles was 15.5%. The almost doubling of the cumulative dropout rate from 15.5% to 26.7% after the third cycle not leading to pregnancy can most likely be explained by the reimbursement policy of the Dutch insurance companies. In most cases they paid only for a maximum of 3 treatment cycles. In our IVF center the maximum number of treatment cycles is usually set on 6. In the cohort 151 of the 351 women not pregnant after 3 cycles (43.0%) continued treatment. For these 151 women this resulted in 44 (29.1%) ongoing pregnancies, live birth rates per treatment cycle being approximately 15.5% for cycle number 4 to 7 (Table 2). The contribution to the overall CLBR may be rather small owing to the small number of patients (an increase from 53.2% to 59.1%), nevertheless continuation after 3 unsuccessful cycles for at least some patients may well be worthwhile, because almost one third of these couples obtained a first live birth after the third treatment cycle. Some women seem to be more fertile than others, even after IVF/ICSI treatment. Taking into account that after each treatment cycle a selection has taken place, the 2 then newly formed groups (pregnant and not pregnant) probably did not share the same characteristics at onset and therefore should not be compared. It is hypothesized that the patients who declined further treatment would have had the same chances as those that continued. After each unsuccessful treatment cycle the ultimate take-home baby chance will decrease and a higher proportion of patients will stop further treatment. Calculation with life table analysis of expected CLBRs overestimates the chances. Usually the reason for discontinuation of treatment is left out, but even when poor prognosis is taken into consideration (14, 15), this does not give all couples a realistic perspective concerning the ultimate treatment outcome. Owing to the considerable dropout rates and the assumption that patients who stop treatment would have had the same chances as those continuing treatment, the theoretically expected birth rate is always overestimated. We compared published data (Table 5, Figs. 2 and 4) and ascertained that the expected birth chances were overrated when established with life table analysis. The level of overrating increases with lower observed pregnancy rates, longer follow-up periods, and higher dropout rates (6 9, 11 16, 20, 21). The dropout rate, and consequently the observed/expected success ratio, seems to be affected by several patient characteristics. This can be illustrated in the studies by Osmanagaoglu et al.: In the testicular sperm extraction (TESE) group (21) as well as in the group FIGURE 3 Live birth rate per cycle (light blue bars) and cumulative live birth rate per patient (dark blue bars) for the LUMC cohort and the transport clinic cohort. a Results are significantly different (P.001). 104 Witsenburg et al. Cohort follow-up of IVF/ICSI patients Vol. 84, No. 1, July 2005
7 TABLE 5 Observed and expected cumulative live birth rates per started patient and ratio expected/observed cumulative live birth rate after 3 and after 5 or more cycles. Live birth rate after 3 cycles (%) Live birth rate after 5 or more cycles (%) Study a Observed Expected Ratio Observed Expected Ratio This study A Olivius et al. (15) B Stolwijk et al. (14) C De Jong et al. (9) D Land et al. (16) E Osmanagaoglu et al. (13) F Osmanagaoglu et al. b (21) G Osmanagaoglu et al. c (21) G Osmanagaoglu et al. (20) H De Mouzon et al. (11) I Dor et al. (6) Alsalili et al. (7) Engmann et al. (8) Fukuda et al. (12) d, 34 y Fukuda et al. (12) d, y Note: Ratio expected/observed cumulative live birth rate. a Studies with their reference number. The studies used in Figure 2 are indicated with the corresponding character. b G1 obstructive azoospermia group (21). c G2 nonobstructive azoospermia group (21). d Results for patients aged under 34 and years, respectively. 37 years of age (20) we see very high overrating ratios. For example, after a long follow-up in the TESE group with nonobstructive azoospermia, the calculated expected live birth rate reaches 65% but the actual observed birth rate is only 18% (Table 2). Patients may withdraw from treatment before a pregnancy has been achieved for various reasons. Financial, geographic, physical, as well as emotional aspects may all influence the decision. Therefore, a reliable estimation of expected birth rates cannot be made when a prognosis is based only on the ovary response to hormone stimulation, the number of oocytes retrieved at the pickup, or the number and quality of the transferred embryos in previous treatment cycles. Even the so-called realistic prognosis is overestimating the success rate (15). Calculation of the expected CLBRs cannot be based on pregnancy rates observed in the group that continue treatment only. Several patient characteristics, such as the indication for IVF/ICSI treatment, previous pregnancies, and woman s age at treatment onset, will influence the final chance of having a baby. It is therefore very important to consider the motivation to discontinue treatment in the patient group with premature treatment dropout. If not, the life table analysis will underestimate the chance of premature treatment dropout and will overrate the cumulative birth rate. As long as one cannot provide all these data, the only true realistic predictor remains the observed CLBR in patient cohorts. Owing to changes in laboratory techniques, ET policies, etc., results may differ over time. The cumulative outcome of yearly cohorts is an important tool to keep track of these changes in order to be able to provide couples accurate up-to-date information about their chances. For instance, the improvement of our ET technique (22) was reflected in the observed success rates for the cohorts started between 1996 and And although the 2000 cohort had an average follow-up period of only 2.5 years, live birth rates are already better than those of the earlier cohorts of From the 1998 cohort onward we see a CLBR of approximately 60%. The cohort method also enables us to show diminishing multiple birth rates as well as the increased influence of cryopreservation, as a consequence of the increasing application of single ET. For the most common IVF/ICSI indications the CLBRs vary from 56% to 63% and do not appear significantly different. This was also observed by Olivius et al. (15). In our study group the highest score was obtained in the subgroup of unexplained infertility in combination with donor semen (74.2%). This group was considered as part of the Fertility and Sterility 105
8 FIGURE 4 Relation of the observed cumulative live birth rate and the overestimation factor. Results after a follow-up period of 3 cycles are shown by the red line; a follow-up of 5 or more cycles is represented by the blue line. Data points refer to Table 5. A the data from this study. unexplained infertility group because all included patients had at least 12 insemination cycles before starting IVF. The high CLBR for these women might be explained by a relative low frequency of female subfertility in combination with good-quality donor semen. With the increase of the women s age at treatment onset the chances of getting pregnant after IVF/ICSI treatment go down significantly (P.01). At the same time chances of early pregnancy loss increase. Nevertheless, in this study the CLBR for women years of age was still 31.3%. Earlier observations showed similar results (8). It is our policy to transfer a limited number of embryos, which makes excessive stimulation unnecessary. This is reflected by the average numbers of oocytes per retrieval and the average number of embryos per transfer; in this study 8.6 and 2.0, respectively. Nevertheless during this study we observed 24.8% twins and 0.9% triplets. Double ET appears to be responsible for half the number of triplets. No selective fetal reduction was performed. Although the birth results presented in this study were high compared with other publications from this period (Table 5), the average multiple birth rate is similar to the mean value observed in 2000 in the whole of Europe. The triplet rate is lower than that published in the last available European report of Assisted Reproduction Technology registries (3). The numbers of twins and triplets reported in our study were 24.8% and 0.9% respectively, whereas the European data showed an average of 24.4% twin births and 2.0% triplet births. Moreover, the multiple birth rate in this study decreased from approximately 30% for the cohorts started between 1996 and 1999 to approximately 20% for the 2000 and 2001 cohorts. Nevertheless, a further decrease in future remained an absolute priority. The major challenge in artificial reproductive technology is to obtain the highest possible birth rates together with the lowest possible numbers of multiple births. To reduce the number of multiples we started in 2002 a protocol for single embryo transfer (SET). In 2003, 29% of all transfers in our center, including the transport clinics, were SETs. The multiple pregnancy rate for fresh stimulated cycles as well as after cryopreservation decreased to 10% and is currently the lowest in The Netherlands (19). The ongoing pregnancy rate per stimulated cycle initiated decreased from around 25% to approximately 20%. Of course it is our concern that the reduction of pregnancy chances remain restricted to an absolute minimum. We believe that embryo cryopreservation can compensate for the decreased pregnancy rates, because 106 Witsenburg et al. Cohort follow-up of IVF/ICSI patients Vol. 84, No. 1, July 2005
9 we saw that the overall ongoing pregnancy rate, with the cryopreservation results included, was hardly affected (between 26% and 28%) after the introduction of the SET protocol (19). The recently proposed BESST as the standard to present the successes obtained with assisted reproduction technology (17) is in our opinion less informative than the cohort method. BESST has the disadvantage that it provides no information about the risk of multiple birth rates. The correlation between BESST and the multiple birth rate is very weak. Even when using the cohort method for determining cumulative birth rates, it remains very difficult to compare results between centers or countries. The outcome is influenced by several variables, such as the transfer policy concerning the number of embryos and the definition of multiple rate (with or without fetal reduction). Moreover, the percentage of multiples considered to be acceptable differs between countries. In conclusion, it can be stated that the cohort follow-up method for determining the crude CLBR is very informative for the patient. This procedure can be used to show the singleton birth rate as well as the risk for a multiple birth. It does not overestimate the success rate and provides a comparison between patient groups and subgroups. Yearly cohorts can be used to trace the effects of changes in treatment policies. Moreover, by defining all kinds of cohorts, the method is easily applicable for comparison between these cohorts. It shows not only the final success rates but also the proportion of patients ending treatment without success. This is in contrast with the popular and widely used life table analysis of the cumulative success rate, which, depending on patients as well as center characteristics, provides us with a considerable overestimation. REFERENCES 1. Steptoe P, Edwards R. Birth after reimplantation of a human embryo. Lancet 1978;2: Assisted reproductive technology in the United States: 1999 results generated from the American Society for Reproductive Medicine/ Society for Assisted Reproductive Technology Registry. Fertil Steril 2002;78: Assisted reproductive technology in Europe, Results generated from European registers by ESHRE. Hum Reprod 2004;19: Hurst T, Lancaster P. Assisted Conception Australia and New Zealand 1999 and Assisted Conception Series No. 6. Sydney: Australian Institute of Health and Welfare National Perinatal Statistics Unit; Bachelot A, Pouly JL, Devecchi A, Quenard A, de Mouzon J FIVNAT general balance. Contracept Fertil Sex 1998;26: Dor J, Seidman DS, Ben-Shlomo I, Levran D, Ben-Rafael Z, Mashiach S. Cumulative pregnancy rate following in-vitro fertilisation: the significance of age and infertility reason. Hum Reprod 1996;11: Alsalili M, Yuzpe A, Tummon I, Parker J, Martin J, Daniel S, et al. Cumulative pregnancy rates and pregnancy outcome after in-vitro fertilisation: 5000 cycles at one centre. Hum Reprod 1995;10: Engmann L, Maconochie N, Bekir JS, Jacobs HS, Tan SL. Cumulative probability of clinical pregnancy and live birth after a multiple cycle IVF package: a more realistic assessment of overall and age-specific success rates? Br J Obstet Gynaecol 1999;106: de Jong D, Eijkemans MJC, Beckers NGM, Pruijsten RV, Fauser BCJM, Macklon NS. The added value of embryo cryopreservation to cumulative ongoing pregnancy rates per IVF treatment: is cryopreservation worth the effort? J Assist Reprod Genet 2002;12: Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958;53: De Mouzon J, Rossin-Amar B, Bachelot A, Renon C, Devecchi A. FIVNAT. Influence of attempt rank in in vitro fertilisation. Contracept Fertil Sex 1998;26: Fukuda J, Kumagai J, Kodama H, Murata M, Kawamura K, Tanaka T. Upper limit of the number of IVF-ET treatment cycles in different age groups, predicted by cumulative take-home baby rate. Acta Obstet Gynaecol Scand 2001;80: Osmanagaoglu K, Tournaye H, Camus M, Vandervorst M, Van Steirteghem A, Devroey P. Cumulative delivery rates after intracytoplasmatic sperm injection: 5 year follow-up of 498 patients. Hum Reprod 1999;14: Stolwijk AM, Wetzels AMM, Braat DDM. Cumulative probability of achieving an ongoing pregnancy after in vitro fertilisation and intracytoplasmatic sperm injection according to a women s age, subfertility diagnosis and primary or secondary subfertility. Hum Reprod 2000;15: Olivius K, Friden B, Lundin K, Bergh C. Cumulative probability of live birth after three in vitro fertilization/intracytoplasmatic sperm injection cycles. Fertil Steril 2002;77: Land JA, Courtar DA, Evers JLH. Patient dropout in an assisted reproductive technology program: implications for pregnancy rates. Fertil Steril 1997;68: Min JK, Breheny SA, MacLachlan V, Healy DL. What is the most relevant standard of success in assisted reproduction? The singleton, term gestation, live birth rate per cycle initiated: the BESST endpoint for assisted reproduction. Hum Reprod 2004;19: Kovacs GT, Maclachlan V, Brehny S. What is the probability of conception for couples entering an IVF program? Aust N Z J Obstet Gynaecol 2001;41: Dutch Society for Obstetrics and Gynaecology. Voorlichting, IVF resultaten, IVF-cyfers per kliniek Available at: files/ivfcijfers2003perkliniek.pdf. Accessed November Osmanagaoglu K, Tournaye H, Kolibianakis E, Camus M, Van Steirteghem A, Devroey P. Cumulative delivery rates after ICSI in women aged 37 years. Hum Reprod 2002;17: Osmanagaoglu K, Vernaeve V, Kolibianakis E, Tournaye H, Camus M, Van Steirteghem A, et al. Cumulative delivery rates after ICSI treatment cycles with freshly retrieved testicular sperm: a 7-year follow-up study. Hum Reprod 2003;18: Naaktgeboren N, Dieben S, Heijnsbroek I, Verburg H, Van der Westerlaken L. Embryo transfer, easier said than done. Embryo transfer (ET) technique, a highly underestimated part of the IVF/ICSI procedure. Fertil Steril 1998;70(Suppl 1):352. Fertility and Sterility 107
Cumulative probability of live birth after three in vitro fertilization/intracytoplasmic sperm injection cycles
FERTILITY AND STERILITY VOL. 77, NO. 3, MARCH 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Cumulative probability
More informationCouples offered free assisted reproduction treatment have a very high chance of achieving a live birth within 4 years
Couples offered free assisted reproduction treatment have a very high chance of achieving a live birth within 4 years Yechezkel Lande, M.D., a Daniel S. Seidman, M.D., b Ettie Maman, M.D., b Micha Baum,
More informationAbstract. Introduction. Materials and methods. Patients and methods
RBMOnline - Vol 8. No 3. 344-348 Reproductive BioMedicine Online; www.rbmonline.com/article/1178 on web 20 January 2004 Article Cumulative live birth rates after transfer of cryopreserved ICSI embryos
More informationA mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort
Chapter 6 A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort Heijnen E.M., Eijkemans M.J., De Klerk C., Polinder S., Beckers N.G., Klinkert E.R.,
More informationHAL author manuscript. Estimating the success of an in vitro fertilization programme. using multiple imputation
HAL author manuscript Human Reproduction / Human Reproduction (Oxford) 2008;23(1):187-92 Estimating the success of an in vitro fertilization programme using multiple imputation N. Soullier 1,2,3, J. Bouyer
More informationCumulative Live-Birth Rates after In Vitro Fertilization
The new england journal of medicine original article Cumulative Live-Birth Rates after In Vitro Fertilization Beth A. Malizia, M.D., Michele R. Hacker, Sc.D., M.S.P.H., and Alan S. Penzias, M.D. ABSTRACT
More informationBody Mass Index and success rate of IVF
Journal of Family and Reproductive Health Summer 2007; (): 4-46 Body Mass Index and success rate of IVF Farshad Savadkouhi M.D., Mina Jafarabadi 2 M.D., Fatemeh Ramezanzadeh 2 M.D. Military University
More informationNICE fertility guidelines. Hemlata Thackare MPhil MSc MRCOG Deputy Medical Director London Women s Clinic
NICE fertility guidelines Hemlata Thackare MPhil MSc MRCOG Deputy Medical Director London Women s Clinic About the LWC 4 centres around the UK London Cardiff Swansea Darlington The largest sperm bank in
More informationOvarian response in three consecutive in vitro fertilization cycles
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in
More informationThe psychological impact of IVF failure after two or more cycles of IVF with a mild versus standard treatment strategy
Human Reproduction Vol.22, No.9 pp. 2554 2558, 2007 Advance Access publication on June 23, 2007 doi:10.1093/humrep/dem171 The psychological impact of IVF failure after two or more cycles of IVF with a
More informationAbstract. Introduction. Materials and methods
RBMOnline - Vol 10. No 5. 2005 645 649 Reproductive BioMedicine Online; www.rbmonline.com/article/1518 on web 18 March 2005 Article Factors predicting IVF treatment outcome: a multivariate analysis of
More information*Correspondence address.
Human Reproduction, Vol.31, No.1 pp. 93 99, 2016 Advanced Access publication on November 3, 2015 doi:10.1093/humrep/dev270 ORIGINAL ARTICLE Infertility How do cumulative live birth rates and cumulative
More informationModified natural cycle IVF and mild IVF: a 10 year Swedish experience
Reproductive BioMedicine Online (2010) 20, 156 162 www.sciencedirect.com www.rbmonline.com ARTICLE Modified natural cycle IVF and mild IVF: a 10 year Swedish experience Arthur Aanesen *, Karl-Gösta Nygren,
More informationClinical Policy Committee
Northern, Eastern and Western Devon Clinical Commissioning Group South Devon and Torbay Clinical Commissioning Group Clinical Policy Committee Commissioning policy: Assisted Conception Fertility treatments
More informationCOMMISSIONING POLICY. Tertiary treatment for assisted conception services
Final Version COMMISSIONING POLICY Tertiary treatment for assisted conception services Designated providers for patients registered with a Worcestershire GP BMI The Priory Hospital, Birmingham - 1 - Commissioning
More informationPatient Overview: Invitro Fertilisation
Patient Overview: Overview IVF stands for in-vitro fertilisation i.e. literally fertilisation in a glass dish. You may also hear the term ART used which stands for Assisted Reproductive Technologies. IVF
More informationArticles Cumulative pregnancy rate following IVF and intracytoplasmatic sperm injection with ejaculated and testicular spermatozoa
RBMOnline - Vol 4. No 2. 151 156 Reproductive BioMedicine Online; www.rbmonline.com/article/433 on web 31 January 2002 Articles Cumulative pregnancy rate following IVF and intracytoplasmatic sperm injection
More informationClinical Policy Committee
Clinical Policy Committee Commissioning policy: Assisted Conception Fertility assessment and investigations are commissioned where: A woman is of reproductive age and has not conceived after one (1) year
More informationWHAT IS A PATIENT CARE ADVOCATE?
WHAT IS A PATIENT CARE ADVOCATE? Fertility treatments can be overwhelming. As a member, you have unlimited access to a dedicated Patient Care Advocate (PCA), who acts as your expert resource for discussing
More informationEuropean IVF Monitoring (EIM) Year: 2013
European IVF Monitoring (EIM) Year: 2013 Name of the country Poland Name and full address of the contact person. Anna Janicka, PhD Polish Society of Reproductive Medicine and Embryology Fertility and Sterility
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationWhy do couples drop-out from IVF treatment? A prospective cohort study
Human Reproduction Vol.23, No.9 pp. 2050 2055, 2008 Advance Access publication on June 10, 2008 doi:10.1093/humrep/den219 Why do couples drop-out from IVF treatment? A prospective cohort study M.F.G. Verberg
More informationBlackpool CCG. Policies for the Commissioning of Healthcare. Assisted Conception
1 Introduction Blackpool CCG Policies for the Commissioning of Healthcare Assisted Conception 1.1 This policy describes circumstances in which NHS Blackpool Clinical Commissioning Group (CCG) will fund
More informationPredictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older
Reprod Med Biol (2009) 8:145 149 DOI 10.1007/s12522-009-0023-z ORIGINAL ARTICLE Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older Akihisa
More informationCumulative Birth Rates with Linked Assisted Reproductive Technology Cycles
original article Cumulative Birth Rates with Linked Assisted Reproductive Technology Cycles Barbara Luke, Sc.D., M.P.H., Morton B. Brown, Ph.D., Ethan Wantman, M.B.A., Avi Lederman, B.A., William Gibbons,
More informationBrighton & Hove CCG PLS CONFERENCE Dr Carole Gilling-Smith Medical Director
Brighton & Hove CCG PLS CONFERENCE 2016 Dr Carole Gilling-Smith Medical Director FERTILITY CHALLENGES IN THE NHS A TERTIARY CARE PERSPECTIVE LEARNING OBJECTIVES Understand the pathways through assisted
More informationComplete failure of fertilization in couples with unexplained infertility: implications for subsequent in vitro fertilization cycles
r FERTILITY AND STERILITY Copyright ~ 1993 The American Fertility Society Printed on acid-free paper in U.S.A. Complete failure of fertilization in couples with unexplained infertility: implications for
More informationCumulative newborn rates increase with the total number of transferred embryos according to an analysis of 15,792 ovum donation cycles
Cumulative newborn rates increase with the total number of transferred embryos according to an analysis of 15,792 ovum donation cycles Nicolas Garrido, Ph.D., M.Sc., a Jose Bellver, M.D., a Jose Remohí,
More informationNicolas Garrido, Ph.D., Jose Bellver, M.D., Jose Remohı, M.D., Carlos Simon, M.D., and Antonio Pellicer, M.D.
ASSISTED REPRODUCTION Cumulative live-birth rates per total number of embryos needed to reach newborn in consecutive in vitro fertilization (IVF) cycles: a new approach to measuring the likelihood of IVF
More informationA mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial
A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial Esther M E W Heijnen, Marinus J C Eijkemans, Cora De Klerk, Suzanne Polinder, Nicole G M Beckers, Ellen R Klinkert,
More informationNHS FUNDED TREATMENT FOR SUBFERTILITY. ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs
NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO
More informationInfertility in Women over 35. Alison Jacoby, MD Dept. of Ob/Gyn UCSF
Infertility in Women over 35 Alison Jacoby, MD Dept. of Ob/Gyn UCSF Learning Objectives Review the effect of age on fertility Fertility counseling for the patient >35 - timing - lifestyle - workup Fertility
More informationCLINICAL ASSISTED REPRODUCTION
CLINICAL ASSISTED REPRODUCTION IVF Births and Pregnancies: An Exploration of Two Methods of Assessment Using Life-Table Analysis R. DEONANDAN, 1,4 M. K. CAMPBELL, 1 T. OSTBYE, 2 I. TUMMON, 3 and J. ROBERTSON
More informationASSISTED CONCEPTION NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA & POLICY GUIDANCE
ASSISTED CONCEPTION NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA & POLICY GUIDANCE Version 1.0 Page 1 of 11 MARCH 2014 POLICY DOCUMENT VERSION CONTROL CERTIFICATE TITLE Title: Assisted Conception
More informationAdoption and Foster Care
GLOSSARY Family building via Adoption and Foster Care October 2018 www.familyequality.org/resources A Anonymous Donor: A person who donated sperm or eggs with the intention of never meeting resulting children.
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationThe evidence for insemination versus intercourse or IVF
To inseminate or not: that s the question! The evidence for insemination versus intercourse or IVF B.Cohlen, Genk 2009 There are believers and non-believers Ovarian stimulation protocols (anti-oestrogens,
More informationHALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY. CONTENTS Page
HALTON CLINICAL COMMISSIONING GROUP NHS FUNDED TREATMENT FOR SUBFERTILITY CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO TREATMENT 3 4. DEFINITION
More informationFertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr.
Dr. Shahin Ghadir A Primary Care Approach to Diagnosing and Treating Infertility St. Charles Bend Grand Rounds November 30, 2018 I have no conflicts of interest to disclose. + About SCRC State-of-the-art
More informationEuropean IVF Monitoring (EIM) Year: 2012
European IVF Monitoring (EIM) Year: 2012 Name of the country Poland Name and full address of the contact person. Professor Rafal Kurzawa, MD PhD Wojska Polskiego 103 Street 70-483 Szczecin Poland Telephone
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1998, by the Massachusetts Medical Society VOLUME 9 A UGUST 7, 1998 NUMBER 9 REDUCING THE RISK OF MULTIPLE BIRTHS BY TRANSFER OF TWO EMBRYOS AFTER IN VITRO
More informationInternational Federation of Fertility Societies. Global Standards of Infertility Care
International Federation of Fertility Societies Global Standards of Infertility Care Standard 8 Reducing the incidence of multiple pregnancy following treatment for infertility Name Version number Author
More informationCalculating cumulative live-birth rates from linked cycles of assisted reproductive technology (ART): data from the Massachusetts SART CORS
Calculating cumulative live-birth rates from linked cycles of assisted reproductive technology (ART): data from the Massachusetts SART CORS Judy E. Stern, Ph.D., a Morton B. Brown, Ph.D., b Barbara Luke,
More informationEast and North Hertfordshire CCG. Fertility treatment and referral criteria for tertiary level assisted conception
East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception December 2015 1 1. Introduction This policy sets out the entitlement and service that will
More informationEmbryo Selection after IVF
Embryo Selection after IVF Embryo Selection after IVF Many of human embryos produced after in vitro fertilization carry abnormal chromosomes. Placing a chromosomally normal embryo (s) into a normal uterus
More informationIVF. NHS North West London CCGs
IVF NHS North West London CCGs Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services Adopted by NWL CCGs to be effective from
More informationSt Helens CCG NHS Funded Treatment for Subfertility Policy 2015/16
St Helens CCG NHS Funded Treatment for Subfertility Policy 2015/16 1 Standard Operating Procedure St Helens CCG NHS Funded Treatment for Sub Fertility Policy Version 1 Implementation Date May 2015 Review
More informationFIVNAT-CH Schweizerische Gesellschaft für Reproduktionsmedizin Société Suisse de Médecine de la Reproduction
SGRM / SSMR Schweizerische Gesellschaft für Reproduktionsmedizin FIVNAT-CH Schweizerische Gesellschaft für Reproduktionsmedizin Annual report 2013 Cycles 2012 Version 15.06.2014 Date of analysis 02.12.2013
More informationAssisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi
Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various
More informationIvf day 6 estradiol level
Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3
More informationFertility treatment and referral criteria for tertiary level assisted conception
Fertility treatment and referral criteria for tertiary level assisted conception Version Number Name of Originator/Author Cross Reference V2 East of England Consortium Commissioning Policy for Fertility
More informationSUBFERTILITY. (Defined as involuntary failure to conceive within 12 months with regular coitus)
SUBFERTILITY (Defined as involuntary failure to conceive within 12 months with regular coitus) Clients attending with fertility concerns should have a medical, drug, menstrual, contraception, social and
More informationProspective longitudinal cohort study on cumulative 5-year delivery and adoption rates among 1338 couples initiating infertility treatment
Human Reproduction, Vol.24, No.4 pp. 991 999, 2009 Advanced Access publication on January 9, 2009 doi:10.1093/humrep/den463 ORIGINAL ARTICLE Reproductive epidemiology Prospective longitudinal cohort study
More informationPolicy statement. Fertility treatments. This policy is unchanged from the version approved by the CCG in July 2014.
Policy statement Fertility treatments This policy is unchanged from the version approved by the CCG in July 2014. Title Policy statement: Fertility treatments v2.0 Author Jacky Walters Approved by Kingston
More informationDRAFT Policy for the Provision of NHS funded Gamete Retrieval and Cryopreservation for the Preservation of Fertility
NHS Birmingham and Solihull Clinical Commissioning Group NHS Sandwell and West Birmingham Clinical Commissioning Group DRAFT Policy for the Provision of NHS funded Gamete Retrieval and Cryopreservation
More informationFertility Policy. December Introduction
Fertility Policy December 2015 Introduction Camden Clinical Commissioning Group (CCG) is responsible for commissioning a range of health services including hospital, mental health and community services
More informationFertility treatment and referral criteria for tertiary level assisted conception
Fertility treatment and referral criteria for tertiary level assisted conception Version Number 2.0 Ratified by HVCCG Exec Team Date Ratified 9 th November 2017 Name of Originator/Author Dr Raj Nagaraj
More informationFertility care for women diagnosed with cancer
Saint Mary s Hospital Department of Reproductive Medicine Information for Patients Fertility care for women diagnosed with cancer Contents Page Overview... 2 Our service... 2 Effects of cancer treatment
More informationAssisted reproductive technology and intrauterine inseminations in Europe, 2005: results generated from European registers by ESHRE
Human Reproduction, Vol.1, No.1 pp. 1 21, 2009 doi:10.1093/humrep/dep035 Hum. Reprod. Advance Access published February 18, 2009 ORIGINAL ARTICLE ESHRE Assisted reproductive technology and intrauterine
More informationUvA-DARE (Digital Academic Repository) Intrauterine insemination: Fine-tuning a treatment Custers, I.M. Link to publication
UvA-DARE (Digital Academic Repository) Intrauterine insemination: Fine-tuning a treatment Custers, I.M. Link to publication Citation for published version (APA): Custers, I. M. (2013). Intrauterine insemination:
More informationCOMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES
COMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES Version number V2.3 Responsible individual Author(s) Barry Weaver Trish
More informationLouise Brown born First IVF baby Born to Lesley Brown, bilateral tubal blockage Natural cycle, single egg fertilization
Louise Brown born First IVF baby Born to Lesley Brown, bilateral tubal blockage Natural cycle, single egg fertilization IVF 1878 - first reported attempts at IVF 1959 - IVF births in rabbits in USA 1968
More informationPuerto Rico Fertility Center
Puerto Rico Fertility Center General Information of the In-Vitro Fertilization Program Dr. Pedro J. Beauchamp First test-tube baby IN PUERTO RICO Dr. Pedro Beauchamp with Adlin Román in his arms. Paseo
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationArtigo original/original Article
Artigo original/original Article Análise do registo português de procriação medicamente assistida: 1997-2005 A long-term analysis of the Portuguese assisted reproductive technologies data registry 1997-2005
More informationIntrauterine (IUI) and Donor Insemination (DI) Policy (excluding In vitro fertilisation (IVF) & Intracytoplasmic sperm injection (ICSI) treatment)
Leicester City Clinical Commissioning Group West Leicestershire Clinical Commissioning Group East Leicestershire and Rutland Clinical Commissioning Group POLICY DOCUMENT Intrauterine (IUI) and Donor Insemination
More informationApproved January Waltham Forest CCG Fertility policy
Approved January 2015 Waltham Forest CCG Fertility policy Contents 1 Introduction 1 2 Individual Funding Requests 1 2.1 Eligibility criteria 1 2.2 Number of cycles funded 2 2.3 Treatment Pathway 3 Page
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationCOMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES V2.
COMMISSIONING POLICY FOR IN VITRO FERTILISATION (IVF)/ INTRACYTOPLASMIC SPERM INJECTION (ICSI) WITHIN TERTIARY INFERTILITY SERVICES V2.3 2017 Agreed at Cannock Chase CCG Signature: Designation: Chair of
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More informationPediatrics, Obstetrics and Gynecology, University School of Medicine, Valencia University, Valencia, Spain
Delaying the initiation of progesterone supplementation until the day of fertilization does not compromise cycle outcome in patients receiving donated oocytes: a randomized study María-José Escribá, Ph.D.,
More informationAssisted Reproductive Technology National Summary Report Belgium 2015
Assisted Reproductive Technology National Summary Report Belgium 2015 College van Geneesheren Reproductieve Geneeskunde Collège de Médecins Médecine de la Reproduction College of Physicians Reproductive
More informationFertility Assessment and Treatment Pathway
Rejected referrals sent back to GP Fertility Assessment and Treatment Pathway Patients with fertility problems go to the GP GP Advice and Assessment GP to inform patient of access criteria for NHS-funded
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More informationBritish Journal of Obstetrics and Gynaecology February 1999, Vol106, pp
British Journal of Obstetrics and Gynaecology February 999, Vol06, pp. 65-70 Cumulative probability of clinical pregnancy and live birth after a multiple cycle IVF package: a more realistic assessment
More informationInfertility. Thomas Lloyd and Samera Dean
Infertility Thomas Lloyd and Samera Dean Infertility Definition Causes Referral criteria Assisted reproductive techniques Complications Ethics What is infertility? Woman Reproductive age Has not conceived
More informationT39: Fertility Policy Checklist
Patient Name: Address: Date of Birth: NHS Number: Consultant/Service to whom referral will be made: Institution Lifestyle Information Latest BMI: Latest BP: Smoking Status: Has the patient been referred
More informationHaringey CCG Fertility Policy April 2014
Haringey CCG Fertility Policy April 2014 1 SUMMARY This policy describes the clinical pathways and entry criteria for Haringey patients wishing to access NHS funded fertility treatment. 2 RESPONSIBLE PERSON:
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationHana Park, Chung-Hoon Kim, Eun-Young Kim, Jei-Won Moon, Sung-Hoon Kim, Hee-Dong Chae, Byung-Moon Kang
Original Article Obstet Gynecol Sci 2015;58(6):481-486 http://dx.doi.org/10.5468/ogs.2015.58.6.481 pissn 2287-8572 eissn 2287-8580 Effect of second-line surgery on in vitro fertilization outcome in infertile
More informationFertility assessment and assisted conception
Fertility assessment and assisted conception Dr Geetha Venkat MD FRCOG Director Pulse Learning Women s health 14 September 2016 Disclosure statement Dr Venkat is a director of Harley Street Fertility Clinic.
More informationVanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol
More informationPolicy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018)
Islington CCG Fertility Policy First approved: 29 January 2015 Policy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018) Introduction Islington CCG
More informationNew York Science Journal 2014;7(4)
The Minimal Stimulation Protocol for ICSI: An Alternative Protocol for Ovarian Stimulation Adel Elsayed Ibrahim, MD Assisted Reproductive Unit Azhar University Adel.sayed29@gmail.com Abstract: Background:
More informationFertility Services Commissioning Policy
Fertility Services Commissioning Policy Author: Commissioning Team Version No: Two Policy Effective From: 29 September 2016 Review Date: September 2017 Policy Amendment: 02 August 2017 Document Reader
More informationPolicy statement. Commissioning of Fertility treatments
Policy statement Commissioning of Fertility treatments NB: The policy relating to commissioning of fertility treatments is unchanged from the version approved by the CCG in March 2017. The clinical thresholds
More informationShould we advise patients undergoing IVF to start a cycle leading to a day 3 or a day 5 transfer?
Human Reproduction Vol.19, No.11 pp. 2550 2554, 2004 Advance Access publication August 6, 2004 doi:10.1093/humrep/deh447 Should we advise patients undergoing IVF to start a cycle leading to a day 3 or
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationNHS WEST ESSEX CLINICAL COMMISSIONING GROUP. Fertility Services Commissioning Policy Policy No. WECCG89. This policy replaces all previous versions.
NHS WEST ESSEX CLINICAL COMMISSIONING GROUP Fertility Services Commissioning Policy Policy No. WECCG89 Description This policy replaces all previous versions. This policy sets out the entitlement and service
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationLCCG Fertility Services Commissioning Policy
LCCG Fertility Services Commissioning Policy Author: Emma Dwyer & Dr Fiona Sim Version No: V.4 Policy Effective from: 1 st December 2014 Review Date: December 2015 This policy replaces all previous versions.
More informationOptimizing Fertility and Wellness After Cancer. Kat Lin, MD, MSCE
Optimizing Fertility and Wellness After Cancer Kat Lin, MD, MSCE University Reproductive Care University of Washington Nov. 6, 2010 Optimism in Numbers 5-year survival rate 78% for all childhood cancers
More informationSperm donation Oocyte donation. Hong Kong þ Guideline þ þ Hungary þ þ þ þ Israel þ þ þ þ Italy þ þ þ. Germany þ þ þ þ Greece þ þ þ þ
CHAPTER 8: Donation Although there has been a reduction in the use of donor sperm because of ICSI and the impact of the removal of anonymity in some countries (1), sperm donation is still used and has
More informationSynchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome
Reproductive BioMedicine Online (2012) 24, 527 531 www.sciencedirect.com www.rbmonline.com ARTICLE Synchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome
More informationArticle Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study
RBMOnline - Vol 13. No 2. 2006 166-172 Reproductive BioMedicine Online; www.rbmonline.com/article/2261 on web 19 May 2006 Article Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study
More informationIndependent Review of Assisted Reproductive Technologies
Assisted Reproductive Technologies Review Committee Report of the Independent Review of Assisted Reproductive Technologies APPENDICES Assisted Reproductive Technologies Review Committee APPENDIX A February
More informationINDICATIONS OF IVF/ICSI
PROCESS OF IVF/ICSI INDICATIONS OF IVF/ICSI IVF is most clearly indicated when infertility results from one or more causes having no other effective treatment; Tubal disease. In women with blocked fallopian
More informationTop 10 questions in fertility
Top 10 questions in fertility Mr Rehan Salim MD MRCOG Head of Reproductive Medicine Consultant Gynaecologist & Subspecialist in Reproductive Medicine Imperial College NHS Trust Learning objectives Patient
More informationIs meaningful reporting of national IVF outcome data possible?
Human Reproduction, Vol.00, No.0 pp. 1 5, 2009 doi:10.1093/humrep/dep357 Hum. Reprod. Advance Access published October 9, 2009 OPINION Infertility Is meaningful reporting of national IVF outcome data possible?
More information